Chemotherapy and thrombosis in gynecologic malignancy.
Thromboembolism is a severe and frequent problem in gynecologic malignancy. The average DVT incidence during chemotherapy of 5% might represent the lower range of incidence because < 55% of thrombotic complication manifest clinical signs. However, it seems likely that in addition to chemotherapy other risk factors such as menopausal status, BMI of patients, or type of preceding surgery must coincide before thrombosis manifests. While monitoring of patients using sophisticated coagulation tests did not identify patients' risk for DVT during chemotherapy, an evaluation of the coagulation status before initiating chemotherapy is recommended. Patients with a venous access device (e.g., indwelling central venous catheter or with port cart) are at a particularly high risk for DVT. This has to be considered when cytoreductive therapy is given. Thrombosis prophylaxis, orally or subcutaneously, should only be considered in a subpopulation of patients who offer a combination of the aforementioned risk factors. Thrombosis prevention trials during chemotherapy found a significant reduction of DVT in patients treated with anticoagulants.
von Tempelhoff
G F
GF
Department of Obstetrics and Gynecology, City Hospital of Ruesselsheim, Germany.
Pollow
K
K
Schneider
D
D
Heilmann
L
L
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000097:blood / Q000150:complications / Q000188:drug therapy; D005260:Female; D005833:Genital Neoplasms, Female / Q000097:blood* / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D010051:Ovarian Neoplasms / Q000097:blood / Q000150:complications / Q000188:drug therapy; D020246:Venous Thrombosis / Q000097:blood* / Q000209:etiology
D000970:Antineoplastic Agents